Terns Pharmaceuticals Inc (TERN) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple price target increases, a promising drug pipeline with best-in-class potential, and a bullish technical setup. Despite some insider selling and a lack of immediate AI trading signals, the long-term growth potential outweighs short-term risks.

Technical Analysis

The technical indicators are bullish. The MACD is positive and contracting, the RSI is neutral at 68.041, and moving averages (SMA_5 > SMA_20 > SMA_200) show a strong upward trend. Key support and resistance levels indicate the stock is trading near resistance at R1: 41.593, with potential upside to R2: 42.794.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Strong analyst support with multiple price target increases (up to $
and consistent 'Outperform' or 'Buy' ratings.
Promising Phase 1 CARDINAL data for TERN-701, showing best-in-class efficacy and safety for chronic myeloid leukemia.
Bullish technical indicators and strong upward momentum.

Neutral/Negative Catalysts

Insider selling by ORBIMED Advisors LLC, reducing their stake significantly.
No recent congress trading data or AI trading signals to support short-term trading opportunities.
Financial performance remains weak with no revenue and negative net income.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$24.64M (improved by 12.26% YoY), and a slight EPS decline to -0.27 (-3.57% YoY). While financials are weak, the company is in a clinical-stage development phase, and its valuation is tied to future drug success.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on TERN, with multiple firms raising price targets significantly (up to $60) and highlighting the potential of TERN-701 as a best-in-class treatment for chronic myeloid leukemia. Analysts see a $4.8B opportunity in the frontline CML market, with additional upside in second-line treatments.

11 Analyst Rating

Wall Street analysts forecast TERN stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 40.920

Low

Averages

54.22

High

Current: 40.920

Low

Averages

54.22

High

Leerink

Outperform

initiated

$58

AI Analysis

2026-02-09

Reason

Leerink

Price Target

$58

AI Analysis

2026-02-09

initiated

Outperform

Reason

Leerink initiated coverage of Terns Pharmaceuticals with an Outperform rating and $58 price target. Terns is a clinical-stage biotechnology company developing TERN-701, a next-generation allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia. Early phase 1 TERN-701 CARDINAL data suggest a best-in-class profile, with materially higher molecular response rates and a clean safety profile that affords a wider therapeutic window enabling deeper and more durable target suppression, the firm notes. The frontline CML setting is the primary driver of value for TERN-701, which Leerink sees as a $4.8B opportunity, $32/share in its model. At Terns's current $4B market valuation, conviction in TERN-701's ability to meaningfully penetrate the frontline setting is paramount to the long thesis. The firm forecasts an additional $1.4B of second-line-and-beyond peak revenues or $18/share in its model.

Citizens

Outperform

maintain

$35 -> $57

2025-12-11

Reason

Citizens

Price Target

$35 -> $57

2025-12-11

maintain

Outperform

Reason

Citizens raised the firm's price target on Terns Pharmaceuticals to $57 from $35 and keeps an Outperform rating on the shares. Terns' interim Phase 1 CARDINAL ASH update highlighted the best-in-class profile of TERN-701, the analyst tells investors in a research note. Key additional data points were the high deep molecular response rate, setting it up well in 1L, and the strong activity post asciminib and ponatinib, which is very positive in 2L, Citizens says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TERN

Unlock Now

TERN Should I Buy

TERN Should I Buy

Should You Buy Terns Pharmaceuticals Inc (TERN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch